Page Title
Clinical Trial Finder
Ask About Participating in This Study
Restore CFTR ProteinEnrolling
Phase 3 study of VX-121/tezacaftor/deutivacaftor in children 2 to 5 with cystic fibrosis, protocol number Vertex VX21-121-105 Cohort A2The following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
(this will open in your email program)
Restore CFTR ProteinEnrolling
Phase 3 study of VX-121/tezacaftor/deutivacaftor in children 2 to 5 with cystic fibrosis, protocol number Vertex VX21-121-105 Cohort A2
This study is taking place at multiple care centers across the U.S. It will look at safety and tolerability and how the body processes the drug VX-121/tezacaftor/deutivacaftor in participants with at least one triple-combination responsive CF mutation.
-
Age:
2 Years to 5 Years
-
Mutation(s):
Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
7
-
Length of Participation:
7 weeks
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More